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Abstract 
Purpose: To explore the neuroprotective efficacy of α-lipoic acid (ALA) against hypoxic-ischemic 
encephalopathy (HIE) in neonatal rats.  
Methods: Forty-eight rats (P7-pups) were randomly assigned to one of four groups: group I received 
saline; group II (HI) underwent unilateral carotid artery ligation and hypoxia (92 % N2 and 8 % O2) for 
2.5 h; and groups III and IV (ALA 50 and 100) were treated with 50 or 100 mg ALA/kg for 7 days prior to 
against hypoxic-ischemic (HI) insult. Cerebral antioxidant status, edema, and the levels of inflammatory 
markers were determined. 
Results: ALA administration substantially (p < 0.01) attenuated both cerebral infarct area and degree of 
edema while decreasing the levels of several inflammatory markers (TNF-α, NF-p65, IL-1β, IL-6). In 
addition, in the ALA groups, antioxidant enzyme (SOD, CAT, GSH) activities were significantly elevated, 
while the expressions of TNF-α and IL-1β protein were significantly (p < 0.01) down-regulated.  
Conclusion: The neuroprotective efficacy of ALA in HIE can be attributed to its suppression of both 
oxidative stress and the levels of inflammatory markers. 
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Hypoxic-ischemic encephalopathy (HIE) is a 
severe complication of peripartum asphyxia that 
can result in severe neurological sequelae or 
disabilities and is often fatal [1]. The global 
prevalence of neonatal HIE is ~2 per 1000 term 
live births, of which ~55 % of the affected 
premature children die by the age of 2 years [2]. 
In neonatal HIE, the restricted blood flow 
ultimately causes energy failure, by triggering a 
cascade of immune responses that lead to 
increased excitotoxicity, inflammation, oxidative 
stress, necrosis, and apoptosis [3,4]. Thus, the 
underlying pathophysiology of HIE is oxidative 
stress and inflammation. Based on the increasing 
evidence of a close relationship between the 
degree of oxidative stress and HIE intensity [5,6], 
related research has focused on reining in 
antioxidant and inflammatory activities to reduce 
the severity of HIE. 
 
Alpha-lipoic acid (ALA) is an endogenous 
antioxidant synthesized mainly by the 
mitochondria of the liver, heart, and kidney. 
Dihydrolipoic acid, the reduced form of ALA, has 
generated interest due to its antioxidant activity. 
ALA has two sulfhydryl (thiol) groups and a free 
hydroxyl group that act as electron donors and 
account for the free-radical scavenging activity of 
ALA [7]. In addition, ALA exhibits metal-chelating 
activity and is an essential cofactor for enzymes 
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involved in the Krebs cycle and the electron 
transport chain [8]. ALA also increases 
(regenerates) glutathione (GSH), thereby 
maintaining optimal levels of other antioxidants, 
such as vitamins C and E, superoxide (SOD), 
and catalase (CAT) [9]. Accordingly, among the 
many health-promoting activities of ALA are its 
antioxidant, anti-inflammatory, anti-apoptotic, 
anticancer, cardioprotective, and neuroprotective 
functions [10,11]. Moreover, because of its 
amphiphilic nature, ALA readily penetrates all 
cells and tissues of the body, including the blood-
brain barrier (BBB). ALA also effectively 
increases the production of acetylcholine 
(neurotransmitter) and thereby maintains the 
integrity of the brain [12]. These findings strongly 
suggest a role for ALA in the treatment of various 
neurological disorders. However, only a few 
experimental studies, involving different animal 
and clinical models following traumatic head 
injury, cerebral ischemia, and seizures, have 
examined the neuroprotective nature of ALA 
[7,11,13]. The present study explored the 
neuroprotective efficacy of ALA against hypoxic–
ischemic (HI) brain injury in neonatal rats, by 
evaluating cerebral infarct area, the degree of 
edema, and the levels of several important 






Alpha-lipoic acid, dimethyl sulfoxide, and 
bromophenol blue were purchased from Sigma-
Aldrich (St. Louis, MO, USA). Diaminobenzidine 
tetrahydrochloride, formaldehyde, and 
phosphate-buffered saline (PBS) were supplied 
by Beijing Zhongshan Golden Bridge 
Biotechnology Co. Ltd. (Beijing, China). Toluidine 
blue, isoflurane, pentobarbital sodium, and 2,3,5-
tritriphenyl-tetrazolium chloride were purchased 
from Lingjin Co. Ltd. (Shanghai, China). 
 
Experimental animals  
 
Male Sprague-Dawley rat pups (7 days old, P7), 
weighing 15–20 g were obtained from the 
Experimental Animal Center (Shaanxi, China). 
The neonatal rats were maintained in a room 
with a temperature of 22 ± 3 °C, 55 ± 5 % 
humidity, and 12/12 h light/dark cycles for one 
week with feed and water ad libitum. All 
experimental protocols were approved by the 
Ethics Committee of the Center Hospital of 
Shaanxi Province (approval no. 162015) 
according to the guidelines put forth by the 
National Institutes of Health Guide for the Care 
and Use of Laboratory Animals [14]. 
 
Induction of HIE 
 
After a week of adaptation (P7–P14), the rats 
were exposed to unilateral HI as described by Li 
et al, with slight modifications [15]. Unilateral 
common carotid artery ligation was performed 
with the rats initially anesthetized with 2 % 
isoflurane. After a 1-h recovery period, the rats 
were placed for 2.5 h in a hypoxia chamber (8 % 
O2, 92 % N2) maintained at a temperature of 37 
°C with the assistance of a water bath. They 
were then moved back to their respective dams 
and immediately injected intraperitoneally (i.p.) 
with saline in the control group and ALA in the 
ALA groups as a one-time post-treatment. Based 
on a preliminary dose-dependent study in a 
model of HI (data not shown), the rat pups in the 
ALA groups were treated with 50 and 100 mg 
ALA/kg, administered i.p. for 7 days prior to HI 
induction. In the control rats, ligation was not 
performed and exposure was to normal 
atmospheric conditions rather than to hypoxia. 
 
Experimental protocol  
 
Of the 48 rats initially used in the current study, 5 
died during HI induction (the mortality rate for 
HIE is 15 – 20 %). The rat pups were randomly 
assigned to four groups: saline (sham control, 
group I; n = 12), HI insult (HI group, group II; n = 
10), i.p. injection of 50 mg ALA (dissolved in 2 % 
saline)/kg body weight for 7 consecutive days 
before HI insult (ALA 50+HI; group III; n=10), and 
i.p. injection of 100 mg ALA (dissolved in 2 % 
saline)/kg body weight for 7 consecutive days 
before HI insult (ALA 100+HI: group IV; n = 11). 
All four groups received a one-time post-
treatment with ALA or saline after HI insult. All 
pups were euthanized on day 16 (P16) by i.p. 
sodium pentobarbital injection. Their brains were 
removed immediately and stored at −80 °C. One 
half of the brain was used for morphological 
analysis (infarct area) and the remaining half for 
biochemical and molecular analyses by 





Evaluation of the infarct area  
 
The cerebral infarct area/volume was evaluated 
by 2, 3, 5-triphenyl-tetrazolium chloride (TTC) 
staining as previously reported [15]. Four coronal 
sections (2 mm) were obtained from each brain. 
The sections were stained with 0.1 % TTC 
(Lingjin Co. Ltd, Shanghai, China) at 37 °C for 5 
min, rinsed with PBS, and then fixed with 10 % 
formaldehyde. The Image J analyzing software 
system (ImageJ, Bethesda, MD, USA) was used 
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to evaluate the infarct area according to the 
following equation: infarct area = (total infarct 
area/whole brain section area) × 100%. 
 
Evaluation of cerebral edema  
 
The degree of the cerebral edema was 
determined using the gravimetric method as 
previously described [16]. Briefly, the wet and dry 
weights of the brain samples were determined 
and cerebral edema (CE) was then computed 
based on the water content according Eq 1. 
 
CE (%) = {W - D)/W}100 …………… (1) 
 
where W and D are the wet weight and dry 




Lipid peroxidation and antioxidant enzyme 
assays 
 
The levels of the lipid peroxidation (LPO) product 
malondialdehyde (MDA), the enzymes SOD and 
CAT, and GSH  were determined. MDA was 
measured based on the reduction of  2-
thiobarbituric acid, quantified based on the 
absorbance at 532 nm. SOD was measured as 
the reduction of nitro blue tetrazolium and the 
absorbance at 560 nm; one unit of SOD was the 
amount of enzyme that inhibited the increase in 
absorbance at 560 nm by 50 % under the assay 
conditions. CAT levels were determined based 
on the reduction of hydrogen peroxide (H2O2), 
quantified by the absorbance at 540 nm; one unit 
of CAT activity was the amount that consumed 1 
µmol of H2O2, quantified by the absorbance at 
540 nm. GSH levels were measured based on 
the reduction of o-phthaldialdehyde, quantified by 
measuring the absorbance at 420 nm. All of the 
above assays were carried out using commercial 
kits according to the manufacturer's 
recommended procedure (Nanjing Jiancheng 
Bioengineering Institute, Nanjing, China). The 
biuret method was used to quantify the protein 
content using a BCA protein assay reagent kit 
(Biovision, California, USA). 
 
Assay of NF-κB p65 subunit, TNF-α, IL-1β, 
and IL-6 
 
The concentration of the free p65 subunit of NF-
κB in the nuclear fraction (nuclear/cytosolic 
fractionation kit; Cell Biolabs) of the cerebral 
cortex was determined using an ActivELISA kit 
(Imgenex, San Diego, USA). The levels of the 
proinflammatory cytokines tumor necrosis factor 
(TNF)-α, interleukin (IL)-1β, and IL-6 in the 
cerebral homogenates were measured by ELISA 
kits (sandwich enzyme immunoassay) according 
to the manufacturer's protocol (Thermo Fisher 
Scientific Inc, MA, USA). 
 
Western blot analysis 
 
An equal amount of protein (50 µg/lane) was 
loaded into each well of 8 % polyacrylamide gels, 
subjected to SDS-PAGE, and then transferred to 
a polyvinylidene membrane (PVDF) using a 
semi-dry blotting system (Amersham, 
Buckinghamshire, UK). The PVDF membrane 
was blocked with Tween 20, Tris buffer, and 5 % 
skimmed milk and incubated overnight at 4 °C 
with polyclonal rabbit anti-TNF-α antibody 
(1:1000; Abcam, USA), polyclonal rabbit anti-IL-
1β antibody (1:500; Abcam, USA), or rabbit anti-
rat β-actin (1:500; Zhongshan Biotechnology, 
Beijing). The following day, the probed 
membrane was incubated for 1 h with 
horseradish-peroxidase-conjugated secondary 
antibody (1:1000). The membranes were 
developed using the enhanced 
chemiluminescence system and the intensity of 
the bands on the membrane quantified using 





All data are expressed as the mean ± standard 
deviation. Differences between each 
experimental group were measured using a one-
way analysis of variance and the Statistical 
Package for Social Sciences software, version 
21 (SPSS Inc, Chicago, USA). The least 
significant difference was determined using a 
post-hoc multiple comparison test. A p value < 





Effect of ALA on cerebral infarct area and 
edema  
 
The cerebral infarct area in the neonatal rats was 
evaluated (Figure 1A and B). In the sham control 
group neither cerebral infarct nor edema was 
detected. The infarct area, seen as white 
patches, was significantly larger in the brains of 
the HI rats (group II) than in the brains of the rats 
in the other groups (p < 0.01). In the two ALA 
treatment groups (50 and 100 mg/kg), the 
decreases in the infarct area compared to the HI 
group were significant (p < 0.01) (Figure 1C). 
The water content of the brain was significantly 
higher (p < 0.01) in the brains of pups exposed to 
HI insult than in brains of the control rats 
whereas it was significantly (p < 0.05) lower in  
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Figure 1: Effects of ALA on cerebral infarct area and edema in control and experimental neonatal rats. Coronal 
sections stained with TTC (A) show  white patches, corresponding to ischemia whereas normal, non-ischemic 
tissue stains red. The area of cerebral infarct and the amount of cerebral edema (water content) were expressed 
as percentages (B and C, respectively); **p < 0.01, *p < 0.05; (a) compared with control group, (b) compared with 
HI group 
 
the ALA (50 and 100 mg/kg) groups than in the 
control. These results demonstrate the 
neuroprotective potential of ALA. 
 
Effect of ALA on LPO products and 
antioxidants in control and experimental rats 
 
The effect of ALA pretreatment on the levels of 
LPO products (MDA) and antioxidants in control 
and experimental neonatal rats is shown in Table 
1. The cerebral MDA level was significantly 
higher (p < 0.01) in the HI group than in the 
control whereas SOD and CAT activities as well 
as GSH levels were lower (p < 0.01). In the ALA 
pre-treated (50 and 100 mg/kg) rats, MDA levels 
declined significantly (p < 0.05 and p < 0.01, 
respectively) whereas SOD and CAT activities 
were sigificantly increased, as were GSH levels. 
 
Effect of ALA on the activities of 
inflammatory markers in sham control and 
experimental neonatal rats 
 
Table 2 shows the effect of ALA on the activities 
of key inflammatory markers (NF-κB p65 subunit, 
TNF-α, IL-1β, and IL-6) in control and 
experimental neonatal rats. Inflammatory marker 
levels were significantly higher in the brain 
tissues of HI rats (p < 0.01) than in those of 
control rats. The intraperitoneal administration of 
ALA (50 and 100) resulted in a substantial (p < 
0.01) decrement in pro-inflammatory cytokine.  
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Table 1: Effect of ALA on lipid peroxidation (LPO) and antioxidants in control and experimental neonatal rats 
 







Sham control 2.85±0.25 59.52±6.34 9.13±0.84 0.30±0.03 
HI 2.21±0.22 a** 47.24±5.35 a** 6.85±0.72 a** 0.77±0.06 a** 
ALA 50 + HI 2.53±0.28 b* 53.56±5.67 b* 7.58±0.53 b* 0.53±0.05 b* 
ALA 100 + HI 2.72±0.34 b** 56.44±4.49 b** 7.88±0.97 b* 0.41±0.03 b** 
SOD, superoxide dismutase; CAT, catalase; GSH, glutathione; values are expressed as the mean ± SD; **p < 
0.01, *p < 0.05 (a) compared with the sham control group, (b) compared with the HI-injured group 
 












Sham control 67.53±6.34 125.24±11.40 67.29±6.80 89.34±8.23 
HI 195.62±18.23 a** 255.15±22.55 a** 169.53±16.61 a** 242.34±21.42 a** 
ALA 50 + HI 125.57±11.03 b** 186.45±18.16 b** 120.24±11.12 b* 168.24±16.07 b* 
ALA 100 + HI 84.21±9.64 b** 152.83±14.74 b** 88.34±10.20 b** 112.64±10.09 b** 
TNF-α, tumor necrosis factor-α; IL, interleukin. Values are the mean ± SD: **p < 0.01, *p < 0.05 (a) compared 
with the sham control group, (b) compared with the HI injured group 
 
concentrations, consistent with its anti-
inflammatory potential  
 
Effect of ALA on TNF-α and IL-1β protein 
expression in sham control and experimental 
neonatal rats 
 
The effect of ALA on the levels of TNF-α and IL-
1β in control and experimental rats is shown in 
Figure 2. Both cytokines were significantly up-
regulated (p < 0.05) in the HI group vs. the 
control group. ALA treatment of HI-induced rats 
resulted in a significant down-regulation in the 
levels of these two markers compared to the HI 
group. The agreement between the results of the 
molecular analysis (protein) and the biochemical 
assay provided clear evidence of the anti-
inflammatory effect of ALA. Both doses of ALA 
improved neurological status, although the 
neuroprotective activity of 100 mg of ALA (group 




Figure 2: Effect of ALA on TNF-α (A) and IL-1β (B) protein expression in the cerebral region of control and 
experimental neonatal rats.Values are expressed as the mean ± SD; Lane 1: sham control group; lane 2; HI-
induced group; lane 3: ALA 50 group: lane 4 ALA 100 group; **p < 0.01, *p < 0.05 (a) compared with the control 
group, (b) compared with the HI group. 
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Hypoxic–ischemic brain injury in neonates can 
lead to severe complications, including cerebral 
palsy, epilepsy, motor impairment, and delayed 
neural development, and in many cases, is fatal 
[17]. Among the factors implicated in HIE are the 
over-production of free radicals and the resulting 
inflammatory response [18,19]. Based on the 
well-known antioxidant and anti-inflammatory 
activity of ALA, it was tested in this study as a 
neuroprotective agent against HI injury in 
neonatal rats. Whereas large infarct areas, seen 
as white patches because of impeded blood flow 
(hypoxic condition), were seen in rats in the HI 
group, ALA pre-treatment resulted in a 
substantially smaller infarct area. Connell and 
Saleh similarly demonstrated that the 
administration of lipoic acid together with 
apocynin significantly reduced the infarct area in 
a rat model of ischemia/reperfusion [20], in 
addition to markedly increasing cerebral edema 
levels due to the lack of BBB integrity. In that 
study, treatment with ALA (50 and 100) 
substantially reduced cerebral edema. Our data 
also agree with the findings of Erşahin et al [21], 
who showed that treatment with lipoic acid 
reduced cerebral edema levels by restoring the 
integrity of the BBB and by inhibiting neutrophil 
activation, thereby conferring neuronal 
protection. 
 
The neonatal brain, with its high oxygen 
utilization rate, low levels of antioxidants, high 
content of polyunsaturated fatty acids (PUFA), 
high water content, low degree of myelinization, 
and low availability of redox-active iron, is highly 
susceptible to oxidative stress (damage) [17], 
which is a primary contributor to HIE [22,23]. An 
imbalance between antioxidants and oxidants 
may lead to oxidative stress and thus to damage 
in the form of LPO, especially for neurons in the 
compensatory mode [24].  
 
LPO is a potent oxidative marker used to quantify 
oxidative stress [25]. The cerebral LPO (MDA) 
level is increased during hypoxia because the 
respective neurons are rich in PUFA and have a 
low antioxidant capacity. ALA administration, 
especially 100 vs. 50 mg, significantly reduced 
LPO levels to near normal. Emmez and 
coworkers [12] showed that ALA, with its free-
radical scavenging activity, significantly 
suppressed LPO. 
 
SOD and CAT are important enzymatic 
antioxidants that, together with the antioxidant 
GSH, control the cellular levels of free radicals. 
The activities of SOD, CAT, and GSH were 
notably suppressed in the HI group, which may 
have been due to free-radical generation. Both 
ALA doses (50 and 100 mg/kg) substantially 
improved the activities of SOD, CAT, and GSH. 
The cytoprotective effect of ALA is derived from 
its ability to limit the generation of reactive 
oxygen species, by inhibiting NADPH and 
xanthine oxidase and by effectively activating the 
PI3k/Akt pathway and related proteins [26]. In 
addition, Skibska and Goraca [8], reported that 
thioredoxin (Trx), a redox signaling molecule 
similar to HO-1 and Nrf2, which are highly 
regulated during oxidative stress (hypoxia), is up-
regulated in ALA-treated rats and indirectly 
activates antioxidant expression. Our results are 
also in agreement with those of Turamanlar and 
colleagues [27], who reported that in rats with 
sciatic nerve ischemic injury the elevated MDA, 
SOD, GSH peroxidase, and GSH levels revert to 
normal in response to ALA.  
Oxidative stress and inflammation are interlinked 
responses. The levels of nuclear factor NF-p65 
and pro-inflammatory cytokines such as TNF-α, 
IL-1β, and IL-6 were greatly augmented in the HI 
group. During oxidative stress, the release of 
various pro-inflammatory cytokines is stimulated 
by microglia/astrocytes, which account for the 
increased levels of these inflammatory markers 
during ischemia. Rats treated with two different 
doses of ALA (50 and 100 mg) had significantly 
lower levels of these markers, with much greater 
anti-inflammatory activity achieved with the 
higher dose. Our results are well supported by 
those of Toklu et al [10], who demonstrated that 
the anti-inflammatory effect of lipoic acid can be 
attributed to diminished levels of inflammatory 
cytokines and to the suppression of neutrophil 
infiltration. In addition, ALA abolishes 
microglial/astrocyte activation by inhibiting the 
translocation of activated NF-κB p65 subunits 
from the cytosol to the nucleus, which hampers 
the expression of downstream pro-inflammatory 
cytokines [11,28]. 
 
TNF-α and IL-1β play crucial roles in the early 
phase of the inflammatory response during 
ischemia. As such, they serve as markers of the 
severity of HIE [1,3]. In this study, TNF-α and IL-
1β expression in the cerebral cortex was 
markedly up-regulated in the HI group vs. the 
control group but significantly down-regulated in 
the ALA-treated groups, subsequent to the 
suppression in the latter of both neutrophil 
infiltration and microglial/astrocytes activation. 
Chen and Kunsch [29] proposed that compounds 
activating the Nrf2 pathway significantly lower the 
inflammatory response while acting as effective 
antioxidants. Pre-treatment of the rat pups in this 
study with 50 or 100 mg ALA effectively 
improved their neurological status, although the 
higher dose showed superior neuroprotective 
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activity based on the larger reductions in 
oxidative stress and inflammatory markers. Thus, 
by enhancing the antioxidant status and 
suppressing various inflammatory markers ALA 
could attenuate HIE in neonatal rats. 
 
There were two major limitations to this study. 
First, ALA was administered for 7 days and the 
rats were euthanized on day 16 after HIE 
induction; thus, the long-term neuroprotective 
effect of ALA is unclear. Also, we did not 
examine specific neuronal responses,  such as 
apoptosis, glutamate excitotoxicity, and 
mitochondrial dysfunction. These will be 




The findings of this study demonstrate the 
antioxidant and anti-inflammatory activities of 
ALA. In a neonatal rat model of HIE, ALA 
pretreatment decreases cerebral infarct volume, 
the degree of edema, and the levels of several 
key oxidative stress and inflammatory markers. 
Thus, ALA merits further investigation its 
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